Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quantum Biopharma (QNTM) Accounts Payables (2018 - 2025)

Quantum Biopharma's Accounts Payables history spans 8 years, with the latest figure at $2.0 million for Q4 2025.

  • On a quarterly basis, Accounts Payables fell 39.11% to $2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.0 million, a 39.11% decrease, with the full-year FY2025 number at $2.0 million, down 39.11% from a year prior.
  • Accounts Payables hit $2.0 million in Q4 2025 for Quantum Biopharma, down from $3.3 million in the prior quarter.
  • Over the last five years, Accounts Payables for QNTM hit a ceiling of $7.5 million in Q4 2021 and a floor of $2.0 million in Q4 2025.
  • Historically, Accounts Payables has averaged $4.8 million across 5 years, with a median of $4.2 million in 2023.
  • Biggest five-year swings in Accounts Payables: surged 102.99% in 2021 and later plummeted 40.99% in 2023.
  • Tracing QNTM's Accounts Payables over 5 years: stood at $7.5 million in 2021, then dropped by 5.36% to $7.1 million in 2022, then plummeted by 40.99% to $4.2 million in 2023, then dropped by 22.41% to $3.3 million in 2024, then tumbled by 39.11% to $2.0 million in 2025.
  • Business Quant data shows Accounts Payables for QNTM at $2.0 million in Q4 2025, $3.3 million in Q4 2024, and $4.2 million in Q4 2023.